

PTO/SB/08A (10-01)  
 Approved for use through 10/31/2002. OMB 0651-0031  
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 5 Attorney Docket Number AB-145U

### Complete if Known

Application Number	09/993,085
Filing Date	November 06, 2001
First Named Inventor	Whitehurst, Todd K.
Art Unit	3763
Examiner Name	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
JM	A1 •	US-4,646,744	03-03-1987	Capel	
	A2 •	US-5,188,104	02-23-1993	Wernicke, et al.	
	A3 •	US-5,193,539	03-16-1993	Schulman, et al.	
	A4 •	US-5,193,540	03-16-1993	Schulman, et al.	
	A5 •	US-5,231,988	08-03-1993	Wernicke, et al.	
	A6 •	US-5,263,480	11-23-1993	Wernicke, et al.	
	A7 •	US-5,312,439	05-17-1994	Loeb	
	A8 •	US-5,324,316	06-28-1994	Schulman, et al.	
	A9 •	US-5,405,367	04-11-1995	Schulman, et al.	
	A10 •	US-5,487,739	01-30-1996	Aebischer, et al.	
	A11 •	US-5,496,369	03-05-1996	Howard, III	
	A12 •	US-5,540,734	07-30-1996	Zabara	
	A13 •	US-5,589,183	12-31-1996	Jannetta	
	A14 •	US-5,597,797	01-28-1997	Clark	
	A15 •	US-5,697,975	12-16-1997	Howard, III et al.	
	A16 •	US-5,741,211	04-21-1998	Renirie, et al.	
	A17 •	US-5,782,798	07-21-1998	Rise	
	A18 •	US-5,843,093	12-01-1998	Howard, III	
	A19 •	US-5,919,216	07-06-1999	Houben, et al.	
	A20 •	US-5,989,920	11-23-1999	Gerald, et al.	
	A21 •	US-6,016,449	01-18-2000	Fischell, et al.	
	A22 •	US-6,051,017	04-18-2000	Loeb, et al.	
	A23 •	US-6,093,167	07-25-2000	Houben, et al.	
	A24 •	US-6,129,685	10-10-2000	Howard, III	

TECHNOLOGY CENTER R3700  
 FEB 11 2003  
 RECEIVED

### FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
JM	A25 •	WO-92/13592-A1	08-20-1992	Wernicke, et al.		
	A26 •	WO-93/02743-A1	02-18-1993	Wernicke, et al.		
	A27 •	WO-98/37926-A1	09-03-1998	Schulman, et al.		
	A28 •	WO-98/43700-A1	10-08-1998	Schulman, et al.		
	A29 •	WO-98/43701-A1	10-08-1998	Schulman, et al.		
	A30 •	WO-01/60450-A1	08-23-2001	Meadows, et al.		

Examiner Signature	Joseph Smale	Date Considered	11/28/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

				Complete if Known
Sheet	2	of	5	Attorney Docket Number
				AB-145U

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
JM	A31 •	AHREN, et al., "The Mechanism of Vagal Nerve Stimulation of Glucagon and Insulin Secretion in the Dog", Endocrinology, Vol. 118, No. 4, (April 1986), pages 1551-1557.
	A32 •	AHREN, et al., "Sympathetic Nerve Stimulation Versus Pancreatic Norepinephrine Infusion in the Dog: 1. Effects on Basal Release of Insulin and Glucagon", Endocrinology, Vol. 121, No. 1, (July 1987), pages 323-331.
	A33 •	BEREITER, et al., "CNS Modulation of Pancreatic Endocrine Function Multiple Modes of Expression", Diabetologia, Suppl. 20, (March 1981), pages 417-425.
	A34 •	BERTHOUD, et al., "Characteristics of Gastric and Pancreatic Responses to Vagal Stimulation with Varied Frequencies: Evidence for Different Fiber Calibers?", Journal of the Autonomic Nervous System, Vol. 19, No. 1, (April 1987), pages 77-84.
	A35	BERTHOUD, et al., "Localization of Vagal Preganglionics that Stimulate Insulin and Glucagon Secretion", AM J Physiol, Vol. 258, No. 1 Part 2, (Jan. 1990), pages R160-168.
	A36 •	BLUHER, et al. "Improvement of Insulin Sensitivity After Adrenalectomy in Patients with Pheochromocytoma", Diabetes Care, Vol. 23, No. 10, (October 1, 2000), pages 1591-1592.
	A37 •	BROBECK, JR., "Mechanism of Development of Obesity in Animals with Hypothalamic Lesions", Physiol Rev, Vol. 26, (1946), pages 541-559.
	A38 •	BROGLIO, et al., "Ghrelin, a Natural GH Secretagogue Produced by the Stomach, Induces Hyperglycemia and Reduces Insulin Secretion in Humans", The Journal of Clinical Endocrinology & Metabolism, Vol. 86, No. 10, (Oct. 2001), pages 5083-5086.
	A39 •	CAMERON, et al., "Micromodular Implants to Provide Electrical Stimulation of Paralyzed Muscles and Limbs", IEEE Transactions on Biomedical Engineering, Vol. 44, No. 9, (Sept. 1997), pages 781-790.
	A40 •	DAVALLI, et al., "Abnormal Sensitivity to Glucose of Human Islets Cultured in a High Glucose Medium: Partial Reversibility After an Additional Culture in a Normal Glucose Medium", Journal of Clinical Endocrinology and Metabolism, Vol. 72, (1991), pages 202-208.
	A41 •	DeNICOLA, et al., "Abnormal Regulation of Adrenal Function in Rats with Streptozotocin Diabetes", Horm Metab Res, Vol. 9, (1977), pages 469-473.
	A42 •	DHILLO, et al., "Hypothalami Peptides as Drug Targets for Obesity", Current Opinion in Pharmacology, Vol. 1, No. 6, (2001), pages 651-655.
	A43 •	FRANKISH, et al., "Neuropeptide Y, the Hypothalamus, and Diabetes: Insights Into the Central Control of Metabolism", Peptides, Vol. 16, No. 4, (1995), pages 757-771.
	A44 •	GARDEMANN, et al., "Reinnervation of Pancreatic Islets and Regulation of Insulin Secretion by Hepatic Sympathetic Nerves After Intrportal Transplantation of Islets Into Livers of Diabetic Rats", Experimental and Clinical Endocrinology and Diabetes, Vol. 103, Suppl. 2, (1995), pages 107-111.


Examiner Signature	<i>Joseph S. M. Lee</i>	Date Considered	11/28/03
--------------------	-------------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED  
FEB 11 2003  
TECHNOLOGY CENTER R3700



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3	of	5	Attorney Docket Number
				AB-145U

### CONTINUED - OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JM	A45 • HOLST, et al., "Nervous Control of Pancreatic Endocrine Secretion in Pigs. I. Insulin and Glucagon Responses to Electrical Stimulation of the Vagus Nerves", Acta Physiol Scand, Vol. 111, No. 1, (Jan. 1981), pages 1-7.		
	A46 • HYDE, et al., "Effects of Area Postrema Caudal Medial Nucleus of Solitary Tract Lesions on Food Intake and Body Weight", AM J Physiol, Vol. 244, (1983), pages R577-87.		
	A47 • IONESCU, et al., "Increases in Plasma Insulin Levels in Response to Electrical Stimulation of the Dorsal Motor Nucleus of the Vagus Nerve", Endocrinology, Vol. 112, No. 3, (March 1983), pages 904-910.		
	A48 • JONKERS, et al., "Influence of Cell Number on the Characteristics and Synchrony of Ca <sup>2+</sup> Oscillations in Clusters on Mouse Pancreatic Islet Cells", Journal of Physiology, Vol. 520, Part 3, (Nov. 1999), pages 839-849.		
	A49 • KAKIZAKI, et al., "Neural Regulation of Auto-Grafted Islets of Langerhans", Nippon Geka Gakkai Zasshi, Vol. 89, No. 3, (March 1988), pages 394-397.		
	A50 • KAKIZAKI, et al., "Neural Regulation of Heterotopic Islets of Langerhans", Surgery, Vol. 100, No. 6, (Dec. 1986), pages 997-1002.		
	A51 • KUROSE, et al., "Glucagon, Insulin and Somatostatin Secretion in Response to Sympathetic Neural Activation in Streptozotocin-Induced Diabetic Rats. A study with the Isolated Perfused Rat Pancreas in Vitro", Diabetologia, Vol. 35, No. 11, (Nov. 1992), pages 1035-1041.		
	A52 • KUROSE, et al., "Mechanism of Sympathetic Neural Regulation of Insulin, Somatostatin, and Glucagon Secretion", Am J Physiol, Vol. 258, No. 1 part 1, (Jan. 1990), pages E220-7.		
	A53 • LORRAIN, et al., "Adrenergic and Nonadrenergic Cotransmitters Inhibit Insulin, Secretion During Sympathetic Stimulation in Dogs", AM J Physiol, Vol. 263, No. 1 Part 1, (July 1992), pages E72-8.		
	A54 • MAYFIELD, et al., "A Role for the Agouti-Related Protein Promoter in Obesity and Type 2 Diabetes", Biochemical and Biophysical Research Communications, Vol. 287, No. 2, (Sep. 21, 2001), pages 568-573.		
	A55 • MINAMI, et al., "Electrophysiological Properties and Glucose Responsiveness of Guinea-Pig Ventromedial Hypothalamic Neurons in Vitro", J Physiol, Vol. 380, (1986), pages 127-143.		
	A56 • MISLER, et al., "Electrophysiology of Stimulus-Secretion Coupling in Human Beta-Cells", Diabetes, Vol. 41, No. 10, (Oct. 1992), pages 1221-1228.		
	A57 • MONDAL, et al., "Orexins (hypocretins): Novel Hypothalami Peptides with Divergent Functions", Biochem Cell Biol, Vol. 78, (2000), pages 299-305.		
	A58 • NAKAZATO, et al., "A Role for Ghrelin in the Central Regulation of Feeding", Nature, Vol. 409, No. 6817, (Jan. 11, 2001), pages 194-198.		
	A59 • NISHI, et al., "Vagal Regulation of Insulin, Glucagon, and Somatostatin Secretion in Vitro in the Rat", J Clin Invest, Vol. 79, No. 4, (April 1987), pages 1191-1196.		
	A60 • OOMURA, et al., "Glucose and Osmosensitive Neurons of the Rat Hypothalamus", Nature, Vol. 222, (1969), pages 282-284.		

Examiner Signature		Date Considered	11/28/03
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED  
TECHNOLOGY CENTER R3700  
FEB 11 2003



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB  
control number.

Substitute for form 1449B/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

<b>Complete if Known</b>			
Application Number	09/993,085		
Filing Date	November 06, 2001		
First Named Inventor	Whitehurst, Todd K.		
Group Art Unit	3763		
Examiner Name			
Sheet	4	of	5
Attorney Docket Number			
AB-145U			

**CONTINUED - OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JM	A61	PERKINS, et al., "Activation of Brown Adipose Tissue Thermogenesis by the Ventromedial Hypothalamus", Nature, Vol. 289, (Jan. 1981), pages 401-402.	
	A62	PIERROZ, et al., "Chronic Administration of Neuropeptide Y Into the Lateral Ventricle Inhibits Both the Pituitary-Testicular Axis and Growth Hormone and Insulin-Like Growth Factor I Secretion in Intact Adult Male Rats", Endocrinology, Vol. 137 No. 1, (Jan 1996), pages 3-12.	
	A63	PI-SUNYER, "Pathogenesis of Obesity", Drug Benefit Trends, Vol. 12, Supp A, (2002), pages 28-33.	
	A64	QU, et al., "Agouti-Related Protein is a Mediator of Diabetic Hyperphagia", Regulatory Peptides, Vol. 98, No. 1-2, (April 2, 2001), pages 69-75.	
	A65	RATNER, "Innovations in Managing Type 2 Diabetes", Drug Benefit Trends, Vol. 12, Supp A, (2000), pages 34-43.	
	A66	RAVIER, et al., "Oscillations of Insulin Secretion Can be Triggered by Imposed Oscillations of Cytoplasmic Ca <sup>2+</sup> or Metabolism in Normal Mouse Islets", Diabetes, Vol. 48, No. 12, (Dec. 1999), pages 2374 - 2382.	
	A67	SAHU, et al., "Evidence that Neuropeptide Y Mediates the Central Effect of Leptin on Food Intake in Rat", Brain Research, Vol. 888, No. 2, (Jan 12, 2001), pages 343-347.	
	A68	SAWCHENKO, et al., "The Distribution of Cells of Organ of Serotonin Input to the Paraventricular and Supraoptic Nuclei of the Rat", Brain Research, Vol. 277, (1983) pages 355-360.	
	A69	SHOR-POSNER, et al., "Deficits in the Control of Food Intake After Paraventricular Nucleus Lesions", Physiology and Behavior, Vol. 35, (1985), pages 883-890.	
	A70	TANAKA, et al., "Effects of Intraventricular Administration of Neuropeptide Y on Feeding Behavior in Fasted Female Rats with Ventromedial Hypothalamic Lesions", Regulatory Peptides, Vol. 52, No. 1, (June 16, 1994), pages 47-52.	
	A71	THOMAS, et al., "Reversal of Type II (NIDDM) Diabetes by Pancreas Islet Transplantation: an Emerging New Concept in Pathophysiology of an Enigmatic Disease", Transplantation Proceedings, Vol. 27, No. 6, (Dec. 1995), pages 3167-3169.	
	A72	ZABORSZKY, et al., "Brainstem Projection to the Hypothalamic Paraventricular Nucleus in the Rat, a CCK-Containing Long Ascending Pathway", Brain Research, Vol. 303, (1984), pages 225-231.	
	A73	"Hormones Found in the Brain May Determine How Much You Eat and Affect Obesity and Diabetes", printed 12/12/02, pages 1-2.	
	A74	"Neurogen Commences Phase Ib Human Clinical Trials with Anti-Obesity Drug", printed 12/06/02, page 1.	
	A75	"Obesity: Mechanism: Neuropeptide Y Receptor Antagonists", Neurogen Corporation, printed 08/21/02, pages 1-2.	
	A76	WAHLESTEDT, et al. "Neuropeptide Y and Related Peptides", printed 07/10/01, pages 1-10.	

Examiner Signature	<i>J. Smith</i>	Date Considered	11/28/03
--------------------	-----------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TECHNOLOGY CENTER R3700

FEB 11 2003

RECEIVED



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

5

Complete If Known	
Application Number	09/993,085
Filing Date	November 06, 2001
First Named Inventor	Whitehurst, Todd K.
Group Art Unit	3763
Examiner Name	
Attorney Docket Number	AB-145U

### CONTINUED - OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
W	A77 •	WELLS, WILLIAM A., "Possible Finding on Weight Control", Standford online Report, printed 12/09/02, pages 1-3.	
	A78 •	Clore Laboratory: News Diabetes, Obesity and Metabolic Research, "7June 2001 - Hot topic poster European Obesity Congress", printed 12/12/02, page 1.	
<b>OTHER PRIOR ART - RELATED APPLICATIONS</b>			
	A79 •	WHITEHURST inventor for AB-135U; U.S. Patent Application Serial No. 09/993,086; filed November 06, 2001; entitled "Systems and Methods for Treatment of Obesity and Eating Disorders by Electrical Brain Stimulation and/or Drug Infusion".	
	A80 •	WHITEHURST and McGIVERN inventors for AB-147U; U.S. Patent Application Serial No. 09/993,084; filed November 06, 2001; entitled "Systems and Methods for Modulation of Pancreatic Endocrine Secretion and Treatment of Diabetes".	

Examiner Signature

Date Considered

11/28/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

FEB 11 2003

TECHNOLOGY CENTER 46700



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**Substitute for form 1449A/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

Sheet 1 of 1

Attorney Docket Number AB-1450

**Complete if Known**

Application Number	09/993,085
Filing Date	November 06, 2001
First Named Inventor	Whitehurst, Todd K.
Art Unit	3763
Examiner Name	Han, Mark K.
Attorney Docket Number	AP-1451

## U.S. PATENT DOCUMENTS

**RECEIVED**  
**MAY 28 2003**

TECHNOLOGY CENTER R3700

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup>	-Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

Examiner Signature		Date Considered	11/28/03
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance.

conformance and not considered. Include copy of this form with next communication to applicant.  
3 Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.  
3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the  
year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as  
indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is  
attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.